Table II.

Model parameters related to costs and effectiveness collected from the GENOM 009 trial.

Parameter	BEV+TMZ group	TMZ group
Clinical efficacy, months
Median PFS, months (95% CI)	4.8 (4.0–5.6)	2.2 (2.0–2.5)
Median OS, months (95% CI)	10.6 (6.9–14.3)	7.7 (5.4–10.0)
Probability of grades 3–4 adverse events, %
Hypertension	4.17	0.00
Hemorrhage	2.08	0.00
Gastrointestinal perforation	4.17	0.00
Thrombocytopenia	2.08	11.11
Leucopenia	2.08	4.44
Febrile neutropenia	2.08	4.44
Nausea and vomiting	2.08	0.00
Infection	10.42	6.67
Thrombotic events	4.17	6.67
Asthenia	4.17	2.22
Unit costs, $/months
Bevacizumab,100 mg/4 ml	4140.22	0.00
Temozolomide,100 mg ×5	3,691.64	4,798.422
Cost of tests	60.32	55.36
Hospitalization	47.36	0.00
Absence from work	108.35	78.80
Cost for adverse events	68.71	132.98
Cost for the progressive disease state	1,990.75	1,282.90
Annual discount rate, %	3.00	3.00

BEV, bevacizumab; TMZ, temozolomide; PFS, progression-free survival; PD, progressive disease; OS, overall survival.